Bill
SB 515
West Virginia SB 515 would require drug testing for all office-based MAT participants, with administration by providers and privacy protections.
SB 515 (West Virginia, 2026) – Summary
Section I. Purpose and intent
- The bill requires individuals who receive office-based medication-assisted treatment (MAT) to undergo drug testing.
- Objective: ensure monitoring of substance use among recipients of office-based MAT, with the aim of promoting treatment integrity, public safety, and informed clinical decision-making.
Section II. Key provisions and changes
- Mandatory drug testing for office-based MAT recipients:
- All individuals participating in office-based MAT programs would be subject to regular drug testing.
- Testing specifics (frequency, method, and substances tested) are not provided in the available text; the bill would establish the framework for these details.
- Compliance and administration:
- Pharmacists, clinicians, or program administrators operating office-based MAT would be responsible for arranging and enforcing drug testing.
- Procedures for specimen collection, chain of custody, and confirmation of results would be defined to ensure accuracy and reliability.
- Consequences of positive tests:
- The bill would outline actions for positive test results or refusal to participate in testing (e.g., adjustments to treatment plan, referrals, or other sanctions). Exact penalties or follow-up steps are not stated in the provided text.
- Confidentiality and consent:
- Protections and limits on the disclosure of drug test results would be defined to protect patient privacy, consistent with existing health information laws.
- Reporting and oversight:
- Possible requirements for reporting test outcomes to a state agency or program administrator; potential data collection for program evaluation.
Section III. Affected entities and individuals
- Primary: Adults and/or minors enrolled in office-based MAT programs in West Virginia.
- Providers: Physicians, nurse practitioners, physician assistants, pharmacists, and MAT program staff who administer or oversee MAT and drug testing.
- Payers: State programs, insurers, or Medicaid/Medicare arrangements that cover MAT and associated testing (subject to existing funding frameworks).
Section IV. Procedural and timeline considerations
- Filing and referral history:
- Filed for introduction on January 20, 2026.
- Referred to Health and Human Resources, then Finance; later moved through the Senate committee process.
- Legislative flow:
- Introduced in the Senate and assigned to relevant committees (Health and Human Resources; Finance) for consideration, hearings, and potential amendments.
- Implementation timeline:
- No explicit date provided for when drug testing would commence if enacted; typically, a bill would specify a effective date and any phased implementation.
Section V. Practical and policy implications
- Public health and safety:
- Regular drug testing could deter and detect illicit substance use among MAT participants, potentially reducing relapse risk and informing safe medication management.
- Treatment access and privacy balance:
- The policy must balance monitoring with patient privacy, ensuring testing does not create undue barriers to access or stigmatize participants.
- Administrative impact:
- Programs would need procedures, staffing, and budget to handle testing logistics, confirmatory testing, and result reporting.
Notes
- The provided text appears to include corrupted or non-textual data for the bill’s substantive sections. The summary above is based on the bill title and typical statutory language for such measures, and highlights the main themes: mandate of drug testing for office-based MAT recipients, administration by providers, and privacy safeguards, with standard legislative process and timelines.
If you’d like, I can tailor this summary to a specific audience (e.g., policymakers, clinicians, or the general public) or add a comparison with current WV MAT regulations.
Compiled from official sources — confirm details with the bill’s official record.
Sign in to ask a question.
